Efavirenz for Healthy Subjects
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Efavirenz for healthy subjects?
Is efavirenz generally safe for humans?
What makes the drug Efavirenz unique compared to other treatments?
Efavirenz is unique because it is a potent, once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI) used for HIV treatment, available as a single 600 mg tablet, which simplifies therapy and reduces the number of pills a patient needs to take, potentially improving adherence and treatment outcomes.210111213
What is the purpose of this trial?
The goal of the study is to learn what happens to levels of MK-7602 in a healthy person's body over time. Researchers will compare what happens to MK-7602 in the body when it is given with or without another medicine called efavirenz, and when it is given with or without a meal.
Research Team
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Eligibility Criteria
This trial is for healthy individuals with a BMI between 18 to 32 kg/m^2. Specific details about who can't join the trial are not provided, but typically participants must meet certain health standards and not be taking conflicting medications.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive MK-7602 with or without efavirenz to study pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Efavirenz
- MK-7602
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University